BD Completes Sales of Ophthalmic Systems Unit and Surgical Blades Product Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...

Hospital & Healthcare Management / Healthcare News :- BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of the sale of its Ophthalmic Systems unit to RoundTable Healthcare Partners and the sale of its surgical blades product platform to one of RoundTable’s portfolio companies, Aspen Surgical Products, Inc.

On June 8, 2010, the Company announced that it had signed agreements to sell certain assets of its BD Medical segment, including the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit. BD expects to complete the sale of the critical care and extended dwell catheter product platforms to Roundtable Healthcare Partners during its fourth fiscal quarter (by September 30, 2010).

The Company expects to record a gain on these sale transactions in the fourth fiscal quarter 2010.  For the full fiscal year 2010, revenues and earnings per share associated with these asset groups were estimated at $200 million and $0.20, respectively.

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »